Drizalma Sprinkle Capsule, Delayed Release
Product Images NDC 47335-619

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Drizalma Sprinkle (NDC 47335-619). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60 mg (B41423b8 Dfec 4d79 Ba3c E43a87803d85 00)

Label for DRIZALMA SPRINKLE 60 mg delayed-release capsules containing duloxetine. The label includes the NDC 47335-619-30, manufacturer Sun Pharmaceutical Industries, Inc., and states to dispense the accompanying Medication Guide to each patient. The label provides storage instructions and cautions such as keeping out of children's reach.*

FDA Label Image

40 mg (B41423b8 Dfec 4d79 Ba3c E43a87803d85 01)

Label for DRIZALMA SPRINKLE duloxetine delayed-release capsules, 40 mg strength, manufactured by Sun Pharmaceutical Industries, Inc. The label notes the product name, dosage form, strength, and quantity of 30 capsules. Instructions for pharmacists and storage conditions are included, along with a barcode and a caution about a missing or broken seal.*

FDA Label Image

30 mg (B41423b8 Dfec 4d79 Ba3c E43a87803d85 02)

Label for DRIZALMA SPRINKLE duloxetine delayed-release capsules, 30 mg strength. The label includes dosage form and route (capsules, oral), NDC 47335-617-30, containing 30 capsules. It states dispensing instructions for pharmacists and manufacturer details of Sun Pharmaceutical Industries, Inc. A barcode and storage instructions are also visible.*

FDA Label Image

Spl-structure (Image 01)

Chemical structure of duloxetine hydrochloride, the active ingredient in DRIZALMA SPRINKLE. The diagram shows the molecular framework including aromatic rings, an oxygen atom, a sulfur-containing ring, and the amine group associated with the HCl salt form.*

FDA Label Image

Spl-figure 1 (Image 02)

A line graph depicting the proportion of patients with relapse over time from randomization to relapse (in days) comparing Duloxetine treatment with Placebo. The graph shows two lines: a solid line for Duloxetine and a dashed line for Placebo, illustrating relapse rates up to approximately 200 days.*

FDA Label Image

Spl-figure 2 (Image 03)

A Kaplan-Meier plot showing the proportion of patients with relapse over time from randomization to relapse in days. The graph compares two treatment groups: placebo (dashed line) and duloxetine (solid line), illustrating relapse rates over approximately 300 days.*

FDA Label Image

Figure 3 (Image 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares the effects of Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo on patient pain improvement, showing trends for each treatment group.*

FDA Label Image

Figure 4 (Image 05)

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline. It compares the efficacy of Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, showing higher patient improvement percentages with duloxetine treatments relative to placebo.*

FDA Label Image

Figure (Image 06)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows percentage of patients improved from 0 to 100%. Duloxetine shows consistently higher patient improvement percentages than placebo across the range.*

FDA Label Image

Figure (Image 07)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline in a study comparing duloxetine 60 mg once daily to placebo. The graph shows two trend lines, one for placebo and one for duloxetine, illustrating patient improvement across increasing pain reduction percentages.*

FDA Label Image

Figure (Image 08)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) over various levels of percent improvement. The graph shows two curves: one for placebo and one for Duloxetine 60/120 mg once daily. The y-axis represents the percentage of patients improved, and the x-axis represents the percent improvement in pain from baseline, ranging from >0 to 100%.*

FDA Label Image

Spl Drizalma 20mg Label

Label for DRIZALMA SPRINKLE 20 mg delayed-release capsules, containing duloxetine. The label includes usage instructions indicating pharmacist dispensing of the Medication Guide. It shows the product NDC, barcode, manufacturer details for Sun Pharmaceutical Industries, Inc., and storage information. The package contains 30 capsules and is labeled for prescription use only.*

FDA Label Image

Spl Drizalma Figure5

A line graph comparing the percent reduction of pain scores versus percent improvement in pain from baseline. The graph plots three treatment groups: Duloxetine Three Daily, Duloxetine Once Daily, and Placebo, showing their pain reduction progress over multiple points.*

FDA Label Image

Spl Drizalma Figure6

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three once-daily doses of duloxetine (20 mg, 30 mg, 60 mg) to placebo, with percent improvement on the x-axis and percentage of patients improved on the y-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.